TERTIARY LYMPHOID STRUCTURES AS MARKERS OF ANTI-TUMOR IMMUNITY WITH INDEPENDENT PROGNOSTIC VALUE IN THE PORTEC-3 TRIAL OF HIGH-RISK ENDOMETRIAL CANCER

被引：0

作者：

Horeweg, N. ^{[1
]}

Workel, H. ^{[2
]}

Loiero, D. ^{[3
]}

Church, D. ^{[4
]}

Vermij, L. ^{[5
]}

Leon-Castillo, A. ^{[5
]}

De Boer, S. ^{[1
]}

Nout, R. ^{[1
,6
]}

Powell, M. ^{[7
]}

Mileshkin, L. ^{[8
]}

Mackay, H. ^{[9
]}

Leary, A. ^{[10
]}

Singh, N. ^{[11
]}

Jurgenliemk-Schulz, I. ^{[12
]}

Creutzberg, C. L. ^{[1
]}

Kolzer, V. ^{[3
,13
,14
]}

Nijman, H. W. ^{[2
]}

Bosse, T. ^{[15
]}

De Bruyn, M. ^{[2
]}

机构：

[1] Leiden Univ Med Ctr LUMC, Dept Radiat Oncol, Leiden, Netherlands

[2] Univ Med Ctr Groningen, Dept Obstet & Gynaecol, Gynaecol Oncol, Groningen, Netherlands

[3] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland

[4] Wellcome Trust Ctr Human Genet, London, England

[5] Leiden Univ Med Ctr LUMC, Dept Pathol, Leiden, Netherlands

[6] Erasmus MC Canc Inst, Dept Radiotherapy, Rotterdam, Netherlands

[7] Barts Hlth NHS Trust, Dept Clin Oncol, London, England

[8] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Med Oncol & Haematol, Toronto, ON, Canada

[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[11] Barts Hlth NHS Trust, Dept Pathol, London, England

[12] UMC Utrecht, Dept Radiat Oncol, Utrecht, Netherlands

[13] Univ Oxford, Dept Oncol, Oxford, England

[14] Nuffield Dept Med, Oxford, England

[15] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷

关键词：

D O I：

10.1136/ijgc-2021-ESGO.156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

482

引用

页码：A99 / A101

页数：3

共 36 条

[31] High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer
Zhan, Zhao
Liu, Shi-jin
Zhang, Yi-ran
Liu, Zhi-long
Zhao, Xiao-xu
Hui, Ding
Pan, Yun-long
Pan, Jing-hua
ANNALS OF MEDICINE, 2023, 55 (01) : 114 - 126
[32] Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial (vol 20, pg 1273, 2019)
de Boer, S. M.
Powell, M. E.
Mileshkin, L.
LANCET ONCOLOGY, 2019, 20 (09): : E468 - E468
[33] A RANDOMIZED TRIAL OF MPA VS CONTROL IN HIGH-RISK (PROGNOSTIC GROUP-3) ENDOMETRIAL CANCER
KNEALE, BLG
MEDICAL AND PEDIATRIC ONCOLOGY, 1983, 11 (03): : 208 - 208
[34] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (vol 19, pg 295, 2018)
de Boer, S. M.
Powell, M. E.
Mileshkin, L.
LANCET ONCOLOGY, 2018, 19 (04): : E184 - E184
[35] PORTEC-3-Studie für Endometriumkarzinome mit hohem Risiko: Auswirkungen der molekularen Klassifizierung auf die Prognose und den Nutzen einer adjuvanten TherapieThe PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy
Simone Marnitz
Birgid Schömig-Markiefka
Strahlentherapie und Onkologie, 2021, 197 (3) : 266 - 268
[36] High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
Pierga, J. -Y.
Hajage, D.
Bachelot, T.
Delaloge, S.
Brain, E.
Campone, M.
Dieras, V.
Rolland, E.
Mignot, L.
Mathiot, C.
Bidard, F. -C.
ANNALS OF ONCOLOGY, 2012, 23 (03) : 618 - 624

← 1 2 3 4 →